Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=award_amount" }, "data": [ { "type": "Grant", "id": "10477", "attributes": { "award_id": "75N95021D00001-0-759502200008-1", "title": "STSS PROGRAM SUPPORT & STSS COVID-19 EMERGENCY RESPONSE SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-05-09", "end_date": "2022-08-15", "award_amount": 8237623, "principal_investigator": { "id": 26488, "first_name": "GARY", "last_name": "MAYS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [ "Area", "Award", "Businesses", "COVID-19", "COVID-19 patient", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Complex Analysis", "Contracts", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Development", "Electronic Health Record", "Emergency response", "Ensure", "Environment", "Genomics", "Health", "Image", "Informatics", "Information Technology", "Ingestion", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Pathology", "Privacy", "Productivity", "Pythons", "Radiology Specialty", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Security", "Services", "Statistical Data Interpretation", "Translational Research", "United States", "United States National Institutes of Health", "Viral", "Visualization", "Work", "analytical tool", "cloud based", "cohort", "coronavirus disease", "data enclave", "data harmonization", "genetic variant", "meetings", "multimodal data", "open source", "open source tool", "programs", "protective factors", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "12419", "attributes": { "award_id": "75N93023C00052-0-9999-1", "title": "DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-22", "end_date": "2026-02-15", "award_amount": 8469477, "principal_investigator": { "id": 28367, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2101, "ror": "", "name": "ALIGOS THERAPEUTICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising antiviral against a pathogen with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.", "keywords": [ "Advanced Development", "COVID-19 therapeutics", "COVID-19 treatment", "Chemistry", "Clinical", "Development", "Pathway interactions", "Viral", "efficacy evaluation", "manufacture", "pandemic potential", "pathogen", "pre-clinical", "product development", "research and development", "safety assessment", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "9141", "attributes": { "award_id": "75N92020C00009-P00002-9999-1", "title": "RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-09-30", "award_amount": 8580056, "principal_investigator": { "id": 24916, "first_name": "ANDREW", "last_name": "QUONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advantages include flexibility to rapidly integrate new mutational markers or increase panel size to include additional infectious agents. This platform works with all clinical sample types. 1) Technology Development Our solution leverages Advantaâ„¢ Dx SARS-CoV-2 RT-PCR Assay submitted for an EUA, and two assays under development that can change the landscape for detection. This assay allows for up to 6000 samples per day on a single system. Additional assays address different needs in testing, throughput, specificity and sensitivity. Modifications to the current workflow increases throughput to 48,000 tests per day while maintaining the identity of each sample. To distinguish between SARS-CoV-2 infection and other respiratory viruses, we will deploy our multiplexed capability to create a pan-respiratory panel. Cost estimates are preliminary based on assumptions of volume and distribution model. To enable pre-symptomatic screening, we are working with the DARPA ECHO program on a host response signature that can be run on the same platform. 2) Scaleup In three months our goal is to scale up manufacturing to over one million tests per day delivering 80 million tests by end of year. Investments in incremental capacity will deliver a cumulative run rate of 4.5 million tests per day in mid 2021. These two components provide a robust platform for scale up of testing for SARS-CoV-2 that allows for the simultaneous detection of other respiratory pathogens.", "keywords": [ "2019-nCoV", "Address", "Biological Assay", "COVID-19 testing", "Clinical", "Detection", "Development", "Goals", "Immune response", "Industry", "Infectious Agent", "Investments", "Microfluidics", "Modeling", "Modification", "Mutation", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "SARS-CoV-2 infection", "Sampling", "Sensitivity and Specificity", "Speed", "System", "Testing", "Work", "base", "cost", "cost estimate", "flexibility", "manufacturing scale-up", "programs", "respiratory", "respiratory pathogen", "respiratory virus", "salivary assay", "scale up", "screening", "technology development" ], "approved": true } }, { "type": "Grant", "id": "5096", "attributes": { "award_id": "3UM1AI068618-17S1", "title": "CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection LC 3", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18177, "first_name": "Patricia D.", "last_name": "D'Souza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2006-06-29", "end_date": "2027-11-30", "award_amount": 8696751, "principal_investigator": { "id": 18178, "first_name": "Margaret Juliana", "last_name": "McElrath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 758, "ror": "https://ror.org/007ps6h72", "name": "Fred Hutchinson Cancer Center", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of a natural history trial for acute SARS-CoV-2 infection in hospitalized and non-hospitalized individuals: “A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection.” With the onset of the COVID-19 pandemic, we recognize there is a significant gap in knowledge in the field on the contribution of innate and adaptive immune functions in modifying COVID-19 disease and in clearing viral infection and in the ability of vaccines to prevent or modify COVID-19 disease in SARS-CoV-2 infected individuals. Addressing this gap, the National Institute of Health (NIH) led rapid constitution of the CoVPN, partnering 5 NIH supported clinical trial networks, to create an enhanced network of physician scientists at 64 United States (US) and 55 international clinical trial sites in 15 countries dedicated to developing globally effective vaccines for SARS-CoV-2. Due to its extensive experience implementing global HIV vaccine trials over the last 20 years, the HIV Vaccine Trials Network (HVTN) LOC was selected as the LOC for CoVPN vaccine trials. We believe the CoVPN is well placed to study the natural history gaps and rapidly deploy this information in the development of SARS-CoV-2 neutralizing vaccines and mAb therapies. In this study we propose initiating an observational cohort study of approximately 950 acutely infected persons recruited at 17 United States (US) and 43 international clinical trial sites over an 8 month period. Adults 18 years and older with RT-PCR positive SARS-CoV-2 test results will be enrolled competitively across trial sites until the full cohort is reached. Participants will follow up for 6 clinic visits over a 28 day period and receive a final remote contact one month after the last visit. Participants who experience clinical decompensation will be referred for hospital evaluation. Specific aims of the study are to generate standardized datasets characterizing the SARS-CoV-2 viral kinetics and the quality, magnitude, and kinetics of humoral, innate and cellular immune responses to SARS-CoV-2 infection in asymptomatic and acutely symptomatic participants (in both hospitalized and non-hospitalized individuals) from a diversity of geographic and genetic backgrounds. This natural history study will tell us much about the adaptive immune responses in persons who are acutely infected from SARS-CoV-2 and will shed light on the role the immune system plays in successfully clearance of infection. It will improve our understanding of the dynamics and duration of responses against variants of concern, including Omicron, as well as the epitope specificity and other defining signatures, and will inform rational design and testing of preventive and therapeutic vaccines and monoclonal antibodies. Lastly, this study will inform the network on critical issues associated with implementation of current and future COVID-19 vaccine trials.", "keywords": [ "2019-nCoV", "Acute", "Address", "Adult", "Biological Assay", "Biometry", "COVID-19", "COVID-19 Prevention Network", "COVID-19 outbreak", "COVID-19 pandemic", "COVID-19 test", "COVID-19 vaccine", "Cellular Assay", "Clinic Visits", "Clinical", "Clinical Trials", "Clinical Trials Network", "Cohort Studies", "Communicable Diseases", "Constitution", "Country", "Data Set", "Development", "Disease", "Enrollment", "Epitopes", "Evaluation", "Eye", "Future", "Genetic", "Geography", "Goals", "HIV Vaccine Trials Network", "HIV vaccine", "Health", "Hospitals", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Individual", "Infection", "Infection Control", "International", "Kinetics", "Knowledge", "Laboratories", "Lead", "Leadership", "Light", "Malaria", "Mediating", "Monoclonal Antibodies", "Monoclonal Antibody Therapy", "Morbidity - disease rate", "Natural History", "Outcome", "Participant", "Persons", "Phase", "Physicians", "Play", "Population", "Population Heterogeneity", "Preparation", "Prevention", "Prevention strategy", "Preventive vaccine", "Prospective Studies", "Protocols documentation", "Quality Control", "Randomized Clinical Trials", "Research Methodology", "Reverse Transcriptase Polymerase Chain Reaction", "Risk", "Role", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Sampling", "Scientist", "Serology test", "Site", "Specificity", "Standardization", "System", "Test Result", "Testing", "Typhoid Fever", "United States", "United States National Institutes of Health", "Vaccine Therapy", "Vaccines", "Validation", "Viral", "Virus Diseases", "Visit", "adaptive immune response", "base", "clinical trial analysis", "cohort", "design", "efficacy study", "efficacy trial", "experience", "follow-up", "immune function", "improved", "mortality", "neutralizing vaccine", "operation", "pandemic disease", "prevent", "programs", "quality assurance", "recruit", "response", "therapeutic vaccine", "vaccine trial", "vaccine-induced antibodies", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "9252", "attributes": { "award_id": "75N91019D00024-P00001-759102000025-3", "title": "International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-28", "end_date": "2025-09-27", "award_amount": 8758469, "principal_investigator": { "id": 24984, "first_name": "SALLY", "last_name": "HUNSBERGER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This funding supports a multicenter study of COVID-19 vaccine immunogenicity and durability, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country’s national vaccination programs. The study will be conducted in international sites including those that participate in the Division of Clinical Research Special Projects. This study is unique in that it examines the immunogenicity of multiple different vaccination regimens (both initial and booster) across several countries.", "keywords": [ "2019-nCoV", "Age", "Antibody Response", "Body mass index", "COVID-19 vaccine", "Clinical Research", "Country", "Data", "Funding", "HIV Infections", "Immunization Programs", "Infection", "International", "Measures", "Multicenter Studies", "Participant", "Regimen", "SARS-CoV-2 infection", "Site", "Subgroup", "Vaccination", "Vaccines", "Virus", "comorbidity", "immunogenicity", "study population", "viral genomics" ], "approved": true } }, { "type": "Grant", "id": "8089", "attributes": { "award_id": "75N92021C00001-0-9999-1", "title": "TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-22", "end_date": "2022-02-21", "award_amount": 8919208, "principal_investigator": { "id": 23976, "first_name": "MILAN", "last_name": "PATEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1095, "ror": "", "name": "PATHOGENDX", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1095, "ror": "", "name": "PATHOGENDX", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates. What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months. Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.", "keywords": [ "COVID-19", "Cost Savings", "Exercise", "Performance at work", "Quantitative Reverse Transcriptase PCR", "RADx", "RADx Tech", "Slide", "System", "Technology", "Testing", "Time", "Update", "cost", "variant detection" ], "approved": true } }, { "type": "Grant", "id": "9232", "attributes": { "award_id": "75N93020C00054-P00001-9999-1", "title": "DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-01", "end_date": "2025-08-31", "award_amount": 8955992, "principal_investigator": { "id": 24970, "first_name": "JEFFREY", "last_name": "GLENN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.", "keywords": [ "Advanced Development", "COVID-19", "COVID-19 therapeutics", "Categories", "Chemistry", "Clinical", "Development", "Emerging Communicable Diseases", "National Institute of Allergy and Infectious Disease", "Pathway interactions", "efficacy evaluation", "pre-clinical", "priority pathogen", "product development", "research and development", "safety assessment", "therapeutic candidate", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "5336", "attributes": { "award_id": "0802876", "title": "The Sloan Digital Sky Survey --Phase III", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)", "MID-SCALE INSTRUMENTATION" ], "program_reference_codes": [], "program_officials": [ { "id": 18726, "first_name": "Nigel", "last_name": "Sharp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2008-10-01", "end_date": "2014-09-30", "award_amount": 9000000, "principal_investigator": { "id": 18730, "first_name": "Daniel", "last_name": "Eisenstein", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1397, "ror": "", "name": "Astrophysical Research Consortium", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 18727, "first_name": "David J", "last_name": "Schlegel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 18728, "first_name": "Constance M", "last_name": "Rockosi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 18729, "first_name": "Steven R", "last_name": "Majewski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1397, "ror": "", "name": "Astrophysical Research Consortium", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project builds on the legacy of the two previous Sloan Digital Sky Survey programs (SDSS and SDSS-II). This project consists of four surveys. \n\nThe NSF funding is primarily for the Baryon Oscillation Spectroscopic Survey (BOSS). This survey will measure redshifts of 1.5 million luminous red galaxies and Lyman-alpha absorption towards 160,000 high redshift quasars. These measurements will permit the absolute cosmic distance scale to be determined to a higher precision (1.0-1.5%) than previously achieved and will provide constraints on the equation of state of dark energy. Some of the NSF funds will also be used to support the Apache Point Observatory Galactic Evolution Experiment (APOGEE). This survey will use high-resolution and high signal-to-noise infrared spectroscopy to penetrate the dust that obscures the inner Galaxy from our view, measuring radial velocities, spectral types, and detailed elemental abundances of 100,000 red giant stars to an H magnitude limit of approximately 13.5 across the full range of the Galactic bulge, bar, and disk.\n\nThe first of the non-NSF funded surveys is SEGUE-2 which will measure radial velocities, spectral types, and elemental abundances of 350,000 stars in numerous target categories to a g magnitude limit of approximately 19, which will probe the kinematics and chemical evolution of the outer Milky Way. The final survey, also non-NSF funded, is the Multi-Object APO Radial Velocity Exoplanet Large-area Survey (MARVELS). This will monitor the radial velocities of 11,000 bright stars, with the precision and cadence needed to detect gas giant planets with orbital periods ranging from several hours to two years. These observations will provide a critical statistical data set for testing theories of the formation and dynamical evolution of planetary systems.\n\nThese surveys will produce large, well calibrated, easily accessible public databases supporting astronomical research and educational activities at many levels. The project also includes an active program of education and outreach promoting the data and tools to K-12 and university educators and to the broader public.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6717", "attributes": { "award_id": "2UL1TR001855-06A1", "title": "Southern California Clinical and Translational Science Institute", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-07-01", "end_date": "2027-03-31", "award_amount": 9009695, "principal_investigator": { "id": 22469, "first_name": "Thomas A", "last_name": "Buchanan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22470, "first_name": "Michele D.", "last_name": "Kipke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Contact PD/PI: Buchanan, Thomas A OVERALL COMPONENT Project Summary/Abstract The Southern California Clinical and Translational Science Institute (SC CTSI) is submitting this revision for a third cycle of Clinical and Translational Science Award (CTSA) funding at a time of dramatic growth and opportunity at our hub. The SC CTSI encompasses the University of Southern California (USC) and Children's Hospital of Los Angeles (CHLA), in close partnership with the Los Angeles County Department of Health Services. Our vision is to be a leader in clinical and translational research to benefit diverse communities and special populations. Our approach builds on past success, acknowledging the changing landscape of clinical and translational research (CTR), the priorities of the CTSA program, and the evolving needs of our researchers, trainees, patients and communities. Our scope leverages strengths in clinical, health system, and community research, education and training, within two overarching themes: diversity and impact. Diversity is reflected in the communities, health systems, and scientific disciplines we engage to improve health care and outcomes. Impact encompasses academic productivity as well as benefit to our workforce, health systems, patients, and communities. To pursue our vision in the context of our scope and themes, we propose six specific aims: (1) Workforce Development: Train a highly skilled workforce with the knowledge, skills, and attitudes to conduct rigorous and reproducible research focused on the evolving health needs of diverse communities. (2) Collaboration and Engagement: Create a culture in which team-based research, engaging all stakeholders and following sound principles of team science, is the standard approach to addressing complex challenges in health and research. (3) Integration: Engage our diverse communities to establish clinical research priorities; identify barriers to research; and develop, demonstrate and disseminate innovative approaches to assure fully partnered clinical research across communities and the lifespan. (4) Methods and Process: Apply principles of quality and process improvement to clinical and translational research to develop and share novel approaches to enhance efficiency, quality and impact. (5) Informatics: Provide an agile information ecosystem that encompasses research, clinical care, communities and their environment, providing a holistic view of health and disease and serving as the engine for discovery, innovation and insight. (6) CTSA Hub: Participate in CTSA network activities, conduct multi-site studies, adopt successful models from peers, and develop, demonstrate and disseminate innovative approaches. Achieving these aims will advance the discipline of CTR directed at improving health in diverse and underserved communities. Glossary ACT – CTSA Program Accrual to Clinical Trials Network IRB – Institutional Review Board BERD – Biostatistics, Epidemiology, Research Design core group ISI – USC Information Sciences Institute CD2H – CTSA Program National Center for Data to Health IT – Information Technology CE – Community Engagement core group KSOM – Keck School of Medicine of USC CEREC – CTSA External Reviewer Exchange Consortium LA – Los Angeles CHDP – Community Health Demonstration Projects LAC DHS – LA County Department of Health Services CHLA – Children's Hospital Los Angeles LGBTQ+ – Lesbian, Gay, Bisexual, Transgender, Questioning CLIC – CTSA Center for Leading Innovation and Collaboration MRC – Mentor Resource Center CLS – Community Listening Session N3C – National COVID Cohort Collaborative CRI – Clinical Research Informatics core group NGHP – Nickerson Gardens Housing Project CSU – Colorado State University NIH – National Institutes of Health CSULA – California State University Los Angeles NLP – Natural Language Processing CTR – Clinical and Translational Research OC/OH-LA – Our Community/Our Health Los Angeles CTTI – Clinical Trials Transformation Initiative PBRN – Practice-Based Research Network DIAMOND – Development, Implementation, and Assessment of Novel Training in Domain-based Competencies Portal QbD – Quality by Design EAC – External Advisory Committee SC CTSI – Southern California Clinical and Translational Science Institute EDWAP – Enterprise Data Warehouse and Analytics Platform SEDoH – Social and Environmental Determinants of Health EHR – Electronic Health Record SNA – Social Network Analysis ERC – Education Resource Center SSI – USC Spatial Sciences Institute FHIR – Fast Healthcare Interoperability Resources STELLAR – Self Career Training Education Lifelong Learning Advancement Resource, a collaboration with Georgia CTSA HACLA – Housing Authority of the City of Los Angeles TBV – Team Building Voucher HDS – Healthcare Delivery Science TIN – Trial Innovation Network HHS – Hollywood, Health & Society TS – Team Science I2b2 – Informatics for Integrating Biology & the Bedside UCLA – University of California Los Angeles ICD – Institutional Career Development URM – Under-Represented in Medicine IIT – Investigator-Initiated Trial USC – University of Southern California IOB – Internal Oversight Board WD – Workforce Development core group Project Summary/Abstract Page 207 Contact PD/PI: Buchanan, Thomas A UL1", "keywords": [ "Address", "Adopted", "Advisory Committees", "African American", "Area", "Artificial Intelligence", "Asian Americans", "Attitude", "Biology", "Biometry", "California", "Child Health Services", "Cities", "Clinical", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Clinical Trials Network", "Clinical and Translational Science Awards", "Collaborations", "Colorado", "Communities", "Community Health", "Community Health Aides", "Community Health Systems", "Competence", "Complement", "Complex", "County", "Data", "Data Analytics", "Development", "Development Plans", "Discipline", "Disease", "Ecosystem", "Electronic Health Record", "Environment", "Fast Healthcare Interoperability Resources", "Fostering", "Funding", "Gardenal", "Glossary", "Goals", "Growth", "Health", "Health Services", "Health system", "Housing", "Improve Access", "Individual", "Informatics", "Information Sciences", "Information Technology", "Institutes", "Institution", "Institutional Review Boards", "Instruction", "Knowledge", "Latino", "Leadership", "Lesbian Gay Bisexual Transgender", "Lesbian Gay Bisexual Transgender Queer", "Longevity", "Los Angeles", "Machine Learning", "Medicine", "Mentors", "Methods", "Mission", "Modeling", "Natural Language Processing", "Pathway Analysis", "Patients", "Pediatric Hospitals", "Peer Review", "Plant Roots", "Population", "Population Heterogeneity", "Population Research", "Process", "Productivity", "Program Sustainability", "Reproducibility", "Request for Applications", "Research", "Research Design", "Research Institute", "Research Personnel", "Research Priority", "Research Training", "Resources", "Role", "Science", "Services", "Site", "Social Network", "Social Sciences", "Societies", "Special Population", "Subgroup", "Talents", "Television", "Time", "Training", "Training and Education", "Translating", "Translational Research", "Translations", "United States National Institutes of Health", "Universities", "Vision", "Work", "Workforce Development", "authority", "base", "care outcomes", "career", "career development", "clinical care", "cohort", "community based participatory research", "community engaged research", "community engagement", "coronavirus disease", "data hub", "data infrastructure", "data warehouse", "design", "education resources", "epidemiology study", "experience", "health care delivery", "health data", "health organization", "improved", "innova" ], "approved": true } }, { "type": "Grant", "id": "14572", "attributes": { "award_id": "2037026", "title": "FMRG: Manufacturing ADvanced Electronics through Printing Using Bio-based and Locally Identifiable Compounds (MADE-PUBLIC)", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "SSA-Special Studies & Analysis" ], "program_reference_codes": [], "program_officials": [ { "id": 8531, "first_name": "Siddiq", "last_name": "Qidwai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": null, "award_amount": 9150001, "principal_investigator": { "id": 25288, "first_name": "Junhong", "last_name": "Chen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 5112, "first_name": "Mark C", "last_name": "Hersam", "orcid": "https://orcid.org/0000-0003-4120-1426", "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": "['http://www.hersam-group.northwestern.edu/']", "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 317, "ror": "https://ror.org/000e0be47", "name": "Northwestern University", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31223, "first_name": "Stuart J", "last_name": "Rowan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31224, "first_name": "Santanu", "last_name": "Chaudhuri", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31225, "first_name": "Elizabeth", "last_name": "Ainsworth", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "This Future EcoManufacturing research grant will enable a future intelligent, scalable, and democratized manufacturing paradigm that allows for distributed printing of low-cost, biodegradable, and recyclable electronic devices using locally identifiable resources, such as bio-based materials derived from plants. These electronic devices are critical components in the rapidly evolving Internet of Things (IoT). The distributed manufacturing can lower overall device costs (by saving transportation costs) and make the supply chain more resilient during disruptions (e.g., during a pandemic). This project will demonstrate as a prototype the distributed printing of a lithium-ion battery (LIB) - powered chemical sensors using plant-derived inks. The printed devices will be used for monitoring growth conditions of hydronic plants that are used to derive the inks. The same platform can be used to print many other sophisticated, biodegradable/recyclable electronic devices using bio-based materials through customization and active learning. Through partnership with community colleges, Manufacturing USA Institutes, and manufacturing incubators, the project aims to educate, train, engage, and excite diverse student audiences and the public on the future sustainable manufacturing through several new, tailored initiatives, such as a cross-institutional certificate program, printable electronics hackathon and DIY initiative, and citizen science competition. <br/><br/>The goal of the project is to enable a manufacturing supply chain from precision agriculture/hydroponics to advanced biodegradable and recyclable electronics. The project will lead to major science advances in three domains: precision growth of plants, manufacturing of tailored bio-based inks, and sustainable production of printable electronics. As a convergent research program, the project will further lead to value-added transferrable and scalable scientific advancements, including novel artificial intelligence/machine learning (AI/ML) algorithms for manufacturing, a framework for designing sustainable and systematically optimized manufacturing processes, and techniques for incorporating heterogeneous data into manufacturing data systems while automatically refining the models. Learned models will correlate plant phenotypes and growth conditions with cellulose and lignin extraction, connect ink formulation with desired ink properties, and associate printing parameters with electronic device performance and quality. The project will lead to an open-source biomaterials-based electronics manufacturing data infrastructure (BEMDI) that fosters innovation through building a community of innovators, educators, and industry partners interested in manufacturing bio-based printable electronics. This Future Manufacturing research is supported by the Divisions of Civil, Mechanical and Manufacturing Innovation (CMMI), Biological Sciences (BIO), Emerging Frontiers and Multidisciplinary Activities (EFMA), Materials Research (DMR), Electrical Communications and Cyber Systems (ECCS), Engineering Education and Centers (EEC), and Mathematical Sciences (DMS).<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1397, "count": 13961 } } }